Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?
Panelists discuss how institutional challenges around chimeric antigen receptor T-cell therapy slot availability and waiting list management influence treatment sequencing decisions and affect subsequent therapy choices in earlier treatment lines for multiple myeloma.
Video content above is prompted by the following:
- How does the issue of slot availability for chimeric antigen receptor (CAR) T-cell therapy, along with the waiting list, fit into the ongoing challenges faced at the institutional level?
- Dr Abdallah to ask Dr Mushtaq: If you choose to use CAR T-cell therapy in earlier lines of therapy, what might you do next and why?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
